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Oncogenic Gain of Function
in Glioblastoma Is Linked to Mutant
p53 Amyloid Oligomers
Murilo M. Pedrote,1 Michelle F. Motta,1 Giulia D.S. Ferretti,1 Douglas R. Norberto,2 Tania C.L.S. Spohr,3
Flavia R.S. Lima,4 Enrico Gratton,5 Jerson L. Silva,1,7,* and Guilherme A.P. de Oliveira1,6,*
SUMMARY
Tumor-associated p53 mutations endow cells with malignant phenotypes, including chemoresistance.
Amyloid-like oligomers of mutant p53 transform this tumor suppressor into an oncogene. However,
the composition and distribution of mutant p53 oligomers are unknown and the mechanism involved
in the conversion is sparse. Here, we report accumulation of a p53mutant within amyloid-like p53 olig-
omers in glioblastoma-derived cells presenting a chemoresistant gain-of-function phenotype. Statisti-
cal analysis from fluorescence fluctuation spectroscopy, pressure-induced measurements, and thiofla-
vin T kinetics demonstrates the distribution of oligomers larger than the active tetrameric form of p53
in the nuclei of living cells and the destabilization of native-drifted p53 species that become amyloid.
Collectively, these results provide insights into the role of amyloid-like mutant p53 oligomers in the
chemoresistance phenotype of malignant and invasive brain tumors and shed light on therapeutic op-
tions to avert cancer.
INTRODUCTION
The p53 tumor suppressor is a key protein involved in the cellular network of different types of cellular stress
(Vousden and Lane, 2007) and the most frequently mutated gene in human cancer (Bisio et al., 2014; Muller
and Vousden, 2013). In response to DNA damage, oncogene activation, genotoxicity, abnormal growth
signals, and hypoxia, the active tetrameric form of this protein functions as a transcription factor that
regulates the expression of a large group of responsive genes involved in apoptosis, cell-cycle arrest
and survival, DNA repair, genomic stability, and senescence (Vousden and Lane, 2007). TP53 mutations
are associated with tumor development, and some result in p53 loss and gain of function and have a domi-
nant-negative effect, which affects cell survival (Ano Bom et al., 2012; Ghosh et al., 2017; Lasagna-Reeves
et al., 2013; Xu et al., 2011; Yang-Hartwich et al., 2015; Zhu et al., 2015).
Seminal in vitro biophysical studies have shown that the core domain of p53 (p53C) aggregates into a
mixture of oligomers and fibrils (Ishimaru et al., 2003a). Additionally, a hotspot mutant of p53C (R248Q)
was shown to seed the aggregation of the wild-type (wt) form of p53 in vitro, a typical behavior of a
prion-like protein (Ano Bom et al., 2012; Silva et al., 2014a). Further models support the existence of coag-
gregation with other transcription factors (Wang and Fersht, 2015). Nevertheless, previous studies have
revealed the occurrence of cell-to-cell transmissibility events involving p53 (Forget et al., 2013; Lee
et al., 2009, 2013), which supports the suggested prion-like nature of this tumor suppressor. The ability
of p53 to aggregate comes from its thermodynamic instability, which causes p53 to unfold near physiolog-
ical temperatures (Bullock et al., 1997). More importantly, conformational changes in wt-p53C (the DNA-
binding domain of p53) generate an aggregation-competent state, ultimately causing p53 aggregation in-
side the cell, which has implications for cancer establishment (Pedrote et al., 2018). For example, in vitro
studies using the fluorescence of p53C have shown the presence of wt-p53C molten globule states prone
to amyloid aggregation (Pedrote et al., 2018). In the same vein, characterization of p53 molten globule
structures under mildly acidic treatment in vitro showed they were present in lysosomal compartments
(Bom et al., 2010). NMR spectroscopy revealed molten globule-like features of p53C in association with
heat shock protein 90 (Hsp90) (Park et al., 2011). Furthermore, different aggregation phenotypes were
observed in biopsies of breast tumor (Levy et al., 2011) and cell lines of different cancers, including breast
(Ano Bom et al., 2012), ovarian (Yang-Hartwich et al., 2015), and prostate cancers (Kluth et al., 2014),
supporting the hypothesis that p53 undergoes misfolding prior to amyloid aggregation in these cells.
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The typical p53 pathway is controlled by the p53-MDM2 axis, triggering the proteasome-dependent
degradation of p53 and surveillance by a negative feedback loop, in which p53 stimulates MDM2 transcrip-
tion (Barak et al., 1993; Montes de Oca Luna et al., 1995; Wu et al., 1993). Although mutant p53 is degraded
through the p53-MDM2 regulatory axis, MDM2 transcription feedback is lost, a condition that favors the
escape of mutant p53 and its accumulation within the cell (Moll and Petrenko, 2003). Conceivably, the
p53 structural instability and deregulation of the intracellular mutant p53 favor a condition in which confor-
mational changes and oligomeric p53 compositions might occur, supporting oncogenic activities. There-
fore, identification and analyses of the oncogenic activities in living cells related to multimeric/oligomeric
mutant p53 species are urgently needed.
Glioblastoma is themost frequent, aggressive, and invasive type of brain tumor (Furnari et al., 2007; Ohgaki
and Kleihues, 2007). The hallmarks of glioblastoma are uncontrolled cellular proliferation, diffuse infiltra-
tion, a propensity for necrosis, robust angiogenesis, strong resistance to apoptosis, and rampant genomic
instability (Milinkovic et al., 2012). Primary and secondary glioblastoma are disease subtypes with different
genetic features. A total of 90% of cases are diagnosed as primary glioblastoma without previous clinical or
histological evidence (Wang et al., 2014). Approximately 30% of primary glioblastomas show TP53 muta-
tions associated with gain-of-function, loss-of-function, and dominant-negative effects (Ham et al., 2019;
Marutani et al., 1999; Wang et al., 2004, 2013). p53 accumulates in the cytoplasm of primary glioblastoma
cells, suggesting its role in tumor pathogenesis (Nagpal et al., 2006). Notably, the M237I-p53 mutation is
present in 0.63% of cancer samples (as cataloged by the International Agency for Research on Cancer,
IARC). Human lymphoblast cell lines containing this mutation showed delayed X-ray-induced apoptosis
(Xia and Liber, 1997) and increased chemosensitivity to temozolomide (TMZ) in glioblastoma cells after
p53 knockdown (Wang et al., 2013), supporting a chemoresistance gain-of-function phenotype. Previous
studies have indicated that p53 regulates the expression of the MGMT gene encoding the O6-methylgua-
nine DNA-methyltransferase protein in fibroblasts and astrocytes. In glioblastoma cells bearing the M237I
p53mutation, p53 knockdown leads to a 5-fold increase in chemosensitivity to TMZ (Wang et al., 2013). The
MGMT protein repairs DNA damage caused by TMZ, indicating a potential p53-dependent drug resis-
tance mechanism. This tumor-associated mutation occurs within the Zn2+-binding site motif at loop 3 of
p53 and drastically affects the p53 DNA-binding ability (Bullock et al., 2000). To the same extent as the hot-
spot mutation R175H, M237I is a destabilizing mutation that has been shown to increase solvent accessi-
bility (Bullock et al., 2000). No mechanistic investigation has assessed the impact of increased solvent
accessibility and hydration on chemoresistant p53 mutants and the consequences for protein oligomeriza-
tion and p53 malignant transformation.
Here, we investigated the aggregation phenotype of a chemoresistant p53 mutant in glioblastoma cells
and the ability of the mutation to promote the formation of p53 multimers that can potentially aggregate
in living cells. We discovered insights into the existence of amyloid-like mutant p53 species in brain tumor
cells presenting a chemoresistance gain-of-function phenotype and the distribution of mutant p53 multi-
mers larger than the active tetrameric form of p53 in living cells. Furthermore, the destabilized mutant is
found in non-native species in solution, which progressively leads to protein misfolding and amyloid aggre-
gation. We found that increased hydration of the mutant leads to an increased tendency to aggregate. The
development of personalized screening tomap how tumor-associated p53mutations affect folding, aggre-
gation, and the malignant oncogenic phenotype of p53 is of fundamental importance toward developing
therapies to avert cancer.
RESULTS
Amyloid Oligomers of a Chemoresistance p53 Mutant Accumulate in Glioblastoma Brain Cell
Tumors
Chemoresistance related to aberrant p53 involves the regulation of several target genes. We confirmed the
increased RNA levels of MGMT and phosphatase and tensin (PTEN) (Figures S1A–S1C) and the increased
cell motility (migration rate) upon scratch formation (Figures S1D and S1E) in T98G glioblastoma cells ex-
pressing a p53 protein withMet-to-Ile substitution at position 237 of p53 compared with wt-p53-expressing
U87 glioblastoma cells. Furthermore, we observed increased chemosensitivity to TMZ treatment in cells
expressing wt-p53 compared with cells expressing the M237I-p53 mutant (Figure S1F). Evaluating the tran-
scriptional profile, we detected decreased p53 and PTEN RNA levels after 48 h of TMZ treatment in wt-p53-
expressing cells but observed no changes in the p53 and PTEN RNA levels in glioblastoma cells carrying
the M237I mutation (Figures S1G and S1H). MGMT was transcribed at higher levels during TMZ treatment
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in T98G cells than in wt-p53-expressing cells, in which MGMT transcription was undetectable within the
studied time period (Figure S1G). These results support previous findings indicating a chemoresistance
phenotype in T98G glioblastoma cells and linking the Met-to-Ile p53 substitution to this gain-of-function
phenotype.
To evaluate whether aggregation of mutant and wt-p53 has a role in the chemoresistance phenotype of
glioblastoma-derived cells, we performed immunofluorescence experiments using confocal microscopy
(Figures 1A–1P and S2A–S2P) of one commercial glioblastoma cell line carrying the wt-p53 sequence
(U87, Figures 1A–1D), one noncommercial cell line obtained from a deceased patient with glioblastoma
(GBM11, Figures 1E–1H), and two glioblastoma cell lines carrying p53 DNA-binding domain mutations;
U138 cells carry the hotspot R273H mutation (Figures 1I–1L), and T98G cells exhibit TMZ chemoresistance
through the M237I mutation (Figures 1M–1P). DNA sequencing of the U87, T98G, and GBM11 cells re-
vealed that the TP53 genes of the U87 and GBM11 cells carried no mutations in the protein DNA-binding
domain, in contrast to T98G cells, in which a codon change (ATG-to-ATA) at position 237 causing a Met-to-
Ile substitution was confirmed (Figure S3).
We observed weak immunostaining for wt-p53 in U87 cells (Figures 1A and S2A). Controversially, for wt-p53
in GBM11 cells, diffuse immunostaining in the cytosol and stronger labeling in the nuclei were observed
(Figures 1E and S2E). These wt-p53-expressing cells exhibited slight colocalization of p53 with oligomeric
structures (Figures 1D and 1E), and most of the colocalized structures were located at the nuclei or in the
perinuclear region (Figures 1D, 1E, S2C, S2D, S2G, and S2H). The T98G cells exhibited more colocalization
of oligomeric structures and M237I-p53 in the nuclei and the perinuclear region (Figures 1M, S2O, and S2P)
than U138 cells (Figures 1I–L, S2K, and S2L), revealing that the M237I-p53 mutant assumes an aggregation-
prone conformation that triggers amyloid oligomerization in this chemoresistant glioblastoma cell type.
Notably, accumulated M237I-p53 amyloid oligomers seem to play a specific role in the chemoresistance
phenotype of these cells, as the glioblastoma cells bearing the hotspot mutant showed negligible p53 ag-
gregation (Figures 1I–L, S2K, and S2L). The colocalization of oligomeric p53 was quantified pixel by pixel
using the correlation between the fluorescent channels in different confocal images (Figures 1Q–1Y,
S2Q–S2Z, and S2AA–S2FF) and Pearson’s coefficient (Figures S4A–S4Q). A high number of pixels within
the double-positive region (labeling number three) of the correlation plots indicates strong colocalization
between p53 and amyloid oligomers in GBM11 (Figures 1R and 1V) and T98G (Figures 1T and 1Y) cells; how-
ever, the correlation between both channels (diagonal distribution of pixels) was more pronounced in glio-
blastoma cells expressing theM237I-p53mutant than in those expressing wt-p53 (Figures 1T, 1Y, S2EE, and
S2FF).
One typical feature of aggregated assemblies is their resistance to harsh treatments. To further support the
existence of aggregated species composed of mutant p53 in T98G cells, we subjected the overall protein
fraction extracted from T98G cells to p53 immunoprecipitation followed by SDS-denaturing gels and im-
munoblots to detect p53. We observed SDS-resistant, high-molecular-weight mutant p53 species using
this approach (Figure S5A). In addition, we observed a diffuse band at approximately 37 kD, which likely
represented proteolytic M237I p53 fragments. In addition, whole H1299 and T98G cell extracts were sub-
jected to size exclusion chromatography (Figure S5B), and eluted fractions were assessed by dot blots to
detect p53 species (Figure S5C). Eluted fractions from T98G cells corresponding to the column void volume
showed positive immunostaining for p53 species (Figure S5C), confirming the presence of high-molecular-
weight p53 assemblies in this glioblastoma cell type.
Excess Formation of Mutant p53 Species Sustains Aggregation in Glioblastoma Cells
As protein accumulation favors misfolding and ultimately aggregation and cell deregulation, we evaluated
the p53 RNA and protein levels in glioblastoma cells expressing wt (U87 and GBM11) andmutant (U138 and
T98G) p53 (Figures 2A–2D and S6). Surprisingly, we observed increased p53 expression at both the RNA
and protein levels in the chemoresistant M237I-p53-expressing cells (Figures 2A–2D). As shown in Fig-
ure 2A, the p53 RNA levels in mutant p53-expressing cells (U138 and T98G) were higher than those in
wt-p53-expressing cells (U87 and GBM11). Densitometric values (Figures 2B and 2D) for the p53 RNA
and protein levels were expressed in correlation plots in which the p53 protein/RNA levels in T98G cells
were different from those in the other cells, suggesting p53 deregulation at the protein level (Figure 2E).
The levels of M237I-p53 in T98G cells were 27.2% higher than M237I-p53 RNA levels, suggesting p53 accu-
mulation in these cells. To further confirmM237I-p53 oligomeric species in this chemoresistant cell line, we
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Figure 1. p53 Amyloid Oligomerization in Chemoresistant Glioblastoma Cells
(A–P) Immunofluorescence panels for (A–D) wt p53-expressing (U87), (E–H) wt p53-expressing (GBM11), (I–L) R273H p53-expressing (U138), and (M–P) M237I
p53-expressing (T98G) glioblastoma cells showing p53 colocalization (white arrows) with amyloid oligomers. Scale bars, 20 mm; (Q–X) Immunofluorescence
panels for (Q) wt p53-expressing (U87), (R) wt p53-expressing (GBM11), (S) R273H p53-expressing (U138), and (T) M237I p53-expressing (T98G) glioblastoma
cells showing merged p53 and amyloid oligomer channels used for pixel-by-pixel quantification. (U–X) Pixel-by-pixel correlation plots between p53 and
oligomer channels. Regions 1, 2, and 3 were classified as +/,/+, and +/+ (p53/oligomers). Pixel frequency is color coded. Pixels within the double-positive
region 3 indicate colocalization between p53 and oligomers. Three independent immunofluorescence experiments were performed with similar results. See
also Figures S2 and S4.
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performed immunoprecipitation of whole U87 and T98G cell extracts using an oligomer-sensitive antibody
followed by p53 immunoblot detection. The results revealed stronger p53 immunostaining in T98G than
U87 cells (Figures 2F and S6) consistent with the immunofluorescence results (Figures 1D and 1M).
To investigate whether the increased M237I-p53 accumulation is potentially related to the presence of
unfolded p53 species and ER stress, we detected the protein levels of two unfolded protein response
(UPR) sensors, inositol-requiring protein-1a (IRE-1a), and protein kinase RNA-like ER kinase (PERK). In
contrast to U138 and GBM11 cells, T98G cells expressed detectable levels of the IRE-1a and PERK sensors,
as shown by immunoblots (Figures S7A–S7D). Notably, U87 cells showed significantly higher levels of these
UPR sensors than other cells, but as the p53 level was negligible, ER stress cannot be attributed to wt-p53
overload in this cell line. Furthermore, we detected equally higher Hsp90 levels in both the M237I-p53-ex-
pressing cells and U87 cells expressing wt-p53 than the Hsp90 levels in the other studied cells (Figure S7D).
Altogether, the accumulation of M237I-p53 (Figure 2) species in glioblastoma cells and the presence of am-
yloid p53 oligomers (Figures 1, S2, and S4) potentially link oligomeric p53 mutant compositions to chemo-
resistance gain-of-function activity in glioblastoma.
Figure 2. Accumulation of M237I-p53 in Glioblastoma Cells
(A) Agarose strips showing the p53 RNA levels in glioblastoma and H1299 cells.
(B) Dot plots showing densitometry values obtained after normalizing p53 transcriptional levels to those of
glyceraldehyde 3-phosphate dehydrogenase, GAPDH. The results are shown as the meanG SEM of three densitometry
measurements. Experiments were performed twice with similar results (***U87 versus U138, p = 0.0005; ***U87 versus
T98G, p= 0.0002; **p= 0.0012, and ns not significant).
(C) Immunoblots (IBs) showing total p53 levels (DO-1) and b-actin as a loading control.
(D) Dot plots showing densitometry values obtained after normalizing p53 protein levels to those of actin. The results are
shown as the meanG SEM of three densitometry measurements. Experiments were performed twice with similar results
(****p< 0.0001, *p= 0.0365).
(E) Correlation plot of p53 RNA versus p53 protein levels in glioblastoma and H1299 cells. (F) Immunoblots (IBs) showing
total p53 levels (input) and the levels of oligomeric p53 in T98G cells after immunoprecipitation (IP) with an oligomer-
sensitive antibody (A11).
See also Figure S6. kD refers to the expected weight of the detected proteins in kilodaltons.
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The Mutant p53 Oligomer Composition in Living Cells
Because M237I-p53 forms amyloid oligomers in glioblastoma cells expressing a chemoresistance gain-of-func-
tion phenotype, we decided to explore the oligomer composition and distribution of this mutant in living cells.
We first detected the different distributions of the EGFP-taggedwt-p53 andM237I-p53 constructs in H1299 cells
(Figure S8). Next, using systematic number and brightness (N&B) analysis of fluorescence fluctuation spectros-
copy data, wedirectlymeasured thewt- andM237I-p53oligomerization status anddistributionwithin living cells.
To exclude any interference from endogenous p53 aggregation, we used p53-null H1299 lung carcinoma cells.
N&B statistical analysis provides a pixel-by-pixel resolution map of the molecular oligomers in living cells by
measuring the average intensity and variance in each pixel in a time series of images (Digman et al., 2008,
2013) (Figures 3A, S9A, and S9B). From these values, the apparent brightness (B maps) and average number
of molecules (N maps) can be estimated (see Transparent Methods). During the acquisition of image frames,
the laser power was set accordingly to eliminate a contribution from photobleaching (see Transparent Methods
and Figures S9C and S9D). The brightness maps directly report the oligomerization status of proteins, as larger
particles generate higher fluorescence fluctuation as they pass in and out of the excitation volume, resulting in
higher variance. Thus, the higher the apparent brightness is, the higher the oligomerization status is, and the
fewer molecules there are within the excitation volume.
Figure 3. Detection of p53 Oligomers in Living Cells
(A) Representative frames of an EGFP-transfected H1299 imaged cell used as input for statistical number and brightness (N&B) analysis.
(B) Representative intensity, brightness (B), and number of molecule (N) maps of an EGFP-transfected H1299 imaged cell.
(C–E)(C) Selection of pixels within brightness plots (red and green squares) (D) or from Gaussians (red and green) of brightness distribution, which can be
used to (E) depict their distribution in imaged cells. Red colors correspond to the immobile fraction (background), and green pixels correspond to
monomeric EGFP.
(F–I) (F and G) and (H and I), Brightness plots of M237I-p53 and wt-p53, respectively, showing different brightness distributions. Intensity, B, and N maps of
imaged (F and G), M237I-p53- and (H and I) wt-p53-expressing cells highlighting bright pixels indicatingM237I-p53 within the nuclei (white arrows). Puncta of
wt-p53, in which an increased number of molecules in N maps do (green arrows) or do not (red arrows) overlap with bright pixels are shown. Red pixels in the
bottom right panels of imaged cells represent cytosolic (red) and nuclear (green) p53 distribution according to Gaussian brightness histograms. All N&B
experiments were performed at least twice with similar results.
See also Figures S9–S11.
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To compare wt and mutant p53 oligomeric states within living cells, we first normalized the brightness
levels of the monomeric EGFP standard (Figures 3A–3E). We obtained an average B value for monomeric
EGFP of 1.21 (n = 7 imaged cells, Figures 3C–3E and S10). Cells transfected with EGFP showed a homoge-
neous distribution of monomeric EGFP throughout the whole cell (Figures 3D, S10, and S11A). Based on
the normalized B value of monomeric EGFP, the oligomeric status and distribution of M237I-p53-EGFP-
transfected (Figures 3F, 3G, and S12A) and wt-p53-EGFP-transfected (Figures 3H, 3I, and S12B) cells
were evaluated. Brightness plots of M237I-p53-transfected (Figures 3F and 3G) and wt-p53-transfected
(Figures 3H and 3I) cells revealed distinctly different distributions (n = 10 imaged cells, Figures 3, S11B,
S11C, and S12). M237I-p53-transfected cells exhibited pixels with higher B values than those of wt-p53-
transfected cells (Figures 3F–3I and S12). B maps of the imaged cells showed that 9 of 10 M237I-p53-trans-
fected cells had brighter pixels than wt-p53-transfected cells either within the nuclei or throughout the
entire cytosol (Figures 3F–3I and S11C, white arrows). In contrast, wt-p53-transfected cells showed a
more homogeneous B map distribution than M237I-p53-transfected cells (Figures S11B and S11C), which
is similar to the findings in monomeric EGFP-transfected cells (Figure S11A). Among 10 imaged wt-p53-
transfected cells, one exhibited brighter pixels within the nuclear region than the imagedM237I-p53-trans-
fected cells (Figure S11B, red asterisk). Interestingly, the distribution of abundant wt-p53 molecules
confined within cytosolic puncta does not predominantly overlap with the bright pixel regions (Figures
3F–3I, S11B, and S12, red arrows), although this finding was not true in all cases (Figures 3F–3I and S11B,
green arrows). Most of the wt-p53 molecules within the puncta overlapped with bright pixels correspond-
ing to assemblies of higher-order aggregates with B values in the range of 3–4 (Figure S13). In M237I-p53-
expressing cells, puncta formation was not observed in the imaged cells and the increased number of
M237I-p53 molecules within the nuclei predominantly overlapped with bright pixels.
To precisely assess the distinct oligomer composition and distribution of wt- and M237I-p53 in living cells,
we used the normalized apparent brightness of monomeric EGFP (B value standard = 1.2) and the following
equation: B = εn + 1 (see Transparent Methods) and estimated B values of 1.4 and 1.8 for p53 dimers and
tetramers, respectively. This implies that B values higher than 2 correspond to species larger than p53 tet-
ramers. We used rectangular slices in brightness plots to indicate the brightness of monomeric (Figures
4A–4F, red), dimeric (Figures 4G–4L, green), and tetrameric (Figures 4M–4R, blue) wt- and M237I-p53 mol-
ecules and the brightness levels for M237I-p53 oligomers (Figures 4S–4U, orange). Pinpointing selected
pixels with different B levels in the imaged cells allowed us to make important conclusions about the dis-
tribution and behavior of wt- and M237I-p53 oligomers. M237I-p53 showed very low cytosolic B levels cor-
responding to monomers and dimers, in contrast to the pronounced cytosolic distribution of M237I-p53
tetramers (Figures 4V–4W). Surprisingly, most B values corresponding to oligomeric M237I-p53 molecules
(at least larger than tetramers) were widely distributed within the nuclei and less densely distributed
throughout the cytosolic region (Figures 4V–4W, white arrowheads). Meanwhile, wt-p53 B values corre-
sponding to monomers and dimers were predominant, and wt-p53 was mostly distributed throughout
the entire cell, whereas tetramers were extremely sparse (Figures 4Y–4AA). Altogether, these results pro-
vide direct evidence of mutant p53 oligomers (larger than tetrameric p53) within the nuclei of living cells.
More important, the mutant p53 used in these studies forms amyloid oligomers in glioblastoma cells that
present a chemoresistance gain-of-function phenotype, a condition conducive to the formation of mis-
folded species.
Increased Hydration Explains the Reduced Structural Integrity and Amyloid Oligomerization
of Mutant p53
To identify the structural determinants causing the distinct composition of mutant p53 oligomers in cells,
we performed in vitro and structural analyses. Met237 is located at the beginning of the L3 loop close to the
Zn2+-binding site, which is similar to the location of the hotspot mutation R175H (Figure S14A). The
S-methyl thioether side chain of Met237 is in close proximity to the His179 imidazole group participating
in the Zn2+ coordinate sphere (Figure S14A). Evaluation of wt- and M237I-p53 hydrophobicity maps re-
vealed that the small increase in hydrophobicity within the mutant p53 Zn2+-binding site explains its desta-
bilization (Figure 5A). In silico mutagenesis showed that, for correct accommodation, the bulky isoleucine
side chainmust move away from the Zn2+-binding site to avoid clashes (Figures 5A and S14A). This situation
potentially impacts the Met237-Cys238-Zn2+ hydrophobic environment and proper zinc coordination
within the L2-L3 interface loops. Furthermore, a stabilizing H-bond occurring between Met237
and Leu194, which is located at the base of loop L2, is disrupted by amino acid substitution. Because
Zn2+ has a structural role in p53 and the hydrophobic environment of Met237 seems to promote proper
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Zn2+ accommodation, we performed guanidine hydrochloride titrations and detected the fluorescence of
intrinsic p53 probes to determine the structural stability of recombinantly expressed M237I-p53C
compared with that of wt-p53C (Figures 5B and 5C). The concentration of guanidine at the midpoint of
the folding transition (G50%) was approximately 0.7 and 1M for M237I-p53C and wt-p53C, respectively, con-
firming the structural role of M237 in maintaining the p53 structural stability (Figures 5C and S14B). This
Figure 4. The Composition of Mutant p53 Oligomers in Living Cells
(A–U) Selection of pixels showing the brightness levels of M237I- and wt-p53 (A–F) monomers (red), (G–L) dimers (green), (M–R) tetramers (blue), and (S–U)
M237I-p53 oligomers (orange).
(V–AA) Distribution of selected pixels in imaged cells expressing (V–W) M237I-p53 and (Y–AA) wt-p53. White arrowheads highlight the predominant
distribution of M237I-p53 oligomers in cellular nuclei. The same color code is used to report oligomeric states throughout the figure. All N&B experiments
were performed at least twice with similar results.
See also Figures S12 and S13.
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mutation affects the conformational ensemble of M237I-p53C native states (N), as theM237I-p53C Tyr fluo-
rescence emission spectra was 60% less intense than that measured for wt-p53C (Figure 5D). As the solvent
polarity was equal in these measurements, the most likely explanation for the pronounced reduction in in-
tensity is the dipolar reorientation of p53 Tyr probes upon excitation due to increased protein hydration.
To test the effects of hydration on the p53C domain and how hydration impacts the p53 Cys3-His1 Zn
2+-binding
motif, we designed pressure jump experiments reporting changes in the fluorescence of p53 intrinsic probes.
Interestingly, M237I-p53C was more sensitive to pressure-induced treatment than wt-p53C (Figure 5E, bottom).
The p50% ofM237I- andwt-p53Cwas approximately 1.6 and 2.6 kbar, respectively, confirming that the hydropho-
bic Met-to-Ile substitution within the Zn2+-binding motif triggers the formation of an ensemble of destabilized
and hydrated structural conformers. The reduced intensity of the Tyr residues at atmospheric pressure inM237I-
Figure 5. Hydrated Mutant p53 States Lead to Aggregation
(A) Hydrophobic maps highlighting increased hydrophobicity within the Zn2+-binding structural motif after Ile237
introduction. (PDB: 2FEJ)
(B) Schematics showing intrinsic tyrosine (green spheres) and single tryptophan (red spheres) fluorescent probes used to
report conformational changes in the p53 DNA-binding domain. Methionine 237 is highlighted in orange. (PDB:2FEJ)
(C) Plot of the fraction of unfolded M237I-p53C and wt-p53C against increasing concentrations of guanidine
hydrochloride (Gu-HCl).
(D) Tyrosine fluorescence emission spectra of M237I- and wt-p53C.
(E) Pressure jump experiments reporting light scattering (LS, top) and changes in the center of spectral mass of M237I-
and wt-p53C. Increased LS measurements at atmospheric pressure represent values obtained after depressurizing the
samples.
(F and G) Collection of fluorescence emission spectra for (F) M237I-p53C and (G) wt-p53C, respectively.
(H and I) Highlights in the different spectral regimens observed for (H) M237I-p53C and (I) wt-p53C, respectively.
See also Figures S14A and S14B. The results are shown as the meanG SEM of at least three independent experiments.
iScience 23, 100820, February 21, 2020 9
p53C indicates the movement of these residues to a more hydrated environment with no predominant loss of
tertiary structure, as no redshift was observedwithin the emission spectra (Figure 5D). The hydrophobic introduc-
tion of Ile237 within the Zn2+-binding structural motif was sufficient to create an ensemble of destabilized and
hydrated conformers prone to amyloid aggregation. If true, it is reasonable to claim that M237I-p53C contains
exposed hydrophobic patches. More interesting is the identification of different emission spectral regimens for
M237I-p53C (Figure 5F) andwt-p53C (Figure 5G).We are aware that the ensemble ofM237I-p53C structural con-
formers (hereafter called N*) is not the same as the wt-p53C native ensemble (hereafter called N) but is instead
composed of a broad population of destabilized native-drifted states exhibiting increased hydration. In contrast
to the spectral regimen observed for wt-p53C, we identified four spectral regimens for M237I-p53C. The first
regimen was common to M237I-p53C (up to 1.4 kbar) and wt-p53C (up to 2.7 kbar), in that there was no appre-
ciable difference in the Tyr emission spectra between theM237I-p53CN* and wt-p53CN states (Figures 5H and
5I; first regimen). The destabilized and hydrated M237I-p53C N* states behaved differently from the wt-p53C N
states within a range between 1.4 and 2.2 kbar. The N* states exposed a single Trp residue, a clear indication of
protein unfolding (Figure 5H; second regimen). Based upon the exposure of the p53 intrinsic probes, pressure-
induced unfolding of wt-p53C N states did not occur, and spectral signals moved directly to the fourth regimen,
inwhichprotein aggregation occurred (Figure 5I; fourth regimen). Aggregationwas shownby the increased scat-
tering contribution within the 300- to 310-nm range (Figure 5I; fourth regimen) and confirmed by light scattering
(LS)measurements (Figure 5E, top). Full unfolding of theM237I-p53N* states was achieved between 2.2 and 2.9
kbar when the spectral signals reached a plateau (Figure 5H; third regimen). This pressure range supports a pop-
ulation of unfolded-drifted species (U*), as small increments in pressure led to aggregation (Figure 5H; fourth
regimen and Figure 5E, top).
To demonstrate that the conformational changes observed in the destabilized non-native species result in
amyloid aggregation, we measured the kinetics of M237I-p53C by scattering and thioflavin T (ThT). In
contrast to what was observed for wt-p53C, M237I-p53C revealed a very short lag phase (20 s) followed
by a sharp increase in both signals up to a plateau at 500 s (Figures 6A and 6B, S14C, and S14D). In the
case of wt-p53C, the lag phase was longer (250 s) than that of M237I-p53C and followed by a smooth
increase in scatter and the ThT signal. Fitting the curves to first-order lag kinetics revealed higher rate con-
stants for the M237I-p53C than wt-p53C (Table 1), suggesting the fast formation of a population of aggre-
gation-competent M237I-p53C conformers at physiological temperature. The ThT fluorescence levels of
M237I-p53C were significantly higher than those of wt-p53C, revealing increased levels of M237I-p53C
amyloid-like species even though a mixture of amyloid-like forms and general aggregation (amorphous +
amyloid) was present, as evidenced by LS (Figures 6C and 6D). Negative staining transmission electron mi-
croscopy showed higher-order assemblies similar to amyloid-like structures composed of the M237I-p53C
(Figure 6E). Finally, by treating wt and M237I-p53C with mild concentrations of guanidine, we observed
increased exposure of hydrophobic patches in M237I-p53C compared with that in wt-p53C (Figure 6F).
Bis-ANS emission spectra showed increased M237I-p53C hydrophobic exposure both in the folded state
and at approximately 50% unfolding (Figures 6G and 6H). These findings confirmed that, by perturbing
overall p53 hydration and protein hydrophobicity to the solvent, the M237I substitution populates desta-
bilized native-drifted species that are preamyloidogenic. Collectively, these findings support a model in
which destabilized aggregation-prone species are formed and contribute to the distinct composition of
an agglomeration of chemoresistance mutant p53.
DISCUSSION
The aggregation phenotypes of p53 observed in breast, ovarian, and prostate tumors have been correlated
with p53 dominant-negative and oncogenic gain-of-function activities (Kluth et al., 2014; Lasagna-Reeves
et al., 2013; Xu et al., 2011). However, there has been no information that p53 can form oligomeric species in
glioblastoma tumors and that agglomeration is associated with chemoresistance oncogenic activity in this
type of brain tumor. Here, we explored questions related to the chemoresistance phenotype involving p53
in glioblastoma with the following aims: (1) identify p53 amyloid oligomers in glioblastoma cells, (2) inves-
tigate the composition and distribution of chemoresistant mutant p53 oligomers in living cells, (3) deter-
mine whether misfolding is a prerequisite for aggregation in cells, and (4) determine the mechanism by
which mutant p53 amyloid aggregation occurs in solution.
The chemoresistance phenotype to TMZ, the standard treatment for glioblastoma, has been linked to a
p53-specific mutation in glioblastoma cells through the increased expression of O6-methylguanine
DNA-methyltransferase (MGMT), an enzyme that repairs DNA damage caused by TMZ (Wang et al.,
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2013). Accordingly, the homologous PTEN tumor suppressor was found to exert oncogenic effects in
mutant p53-expressing glioblastoma cells, including cell cycle progression, cell proliferation, and cell
death inhibition (Li et al., 2008). Compared with those in wt p53-expressing glioblastoma cells, significantly
higher transcript levels of MGMT and PTEN and faster migration in glioblastoma cells with the M237I-p53
mutation that are insensitive to TMZ were detected. The increased MGMT and PTEN transcript levels in
T98G cells support their oncogenic transformation, which is reflected by the acquisition of phenotypes
such as chemoresistance and acceleration of cell proliferation and migration.
Several lines of evidence have indicated that amyloid-like p53 oligomers are present in different tumor cells
and tissues, as shown by using an amyloid oligomer-sensitive antibody (Ano Bom et al., 2012; Ghosh et al.,
2017; Levy et al., 2011). The TMZ-chemoresistant glioblastoma cells showed higher levels of mutant p53
amyloid oligomers than glioblastoma cells expressing either wt p53 or a hotspot p53mutant not associated
with chemoresistance. Abnormal accumulation of wt and mutant p53 was described in different types of
cancer cells, such as neuroblastoma, retinoblastoma, breast cancer, and colon cancer cells (Kluth et al.,
2014; Levy et al., 2011). However, the levels of accumulated wt p53 and p53 mutants drastically differ,
Figure 6. Amyloid Aggregation of M237I-p53 in Solution
(A and B) Normalized thioflavin T (ThT) fluorescence kinetics of (A) M237I- and (B) wt-p53C at physiological temperature.
The k1 and k2 rate constants (Table 1) were obtained after fitting (black lines) the experimental points (red) using first-
order lag kinetics.
(C and D) Dot plots showing (C) ThT fluorescence and (D) light scattering (LS) values after kinetic traces for wt- and M237I-
p53C, respectively.
(E) Negative staining micrographs after kinetic traces for M237I- and wt-p53C. Insets show zoomed areas. Scale bars,
0.2 mm.
(F) Dot plot reporting the fluorescence of bis-ANS and wt- and M237I-p53C hydrophobicity following exposure to the
solvent under increasing concentrations of guanidine hydrochloride, Gu-HCl (0, 0.2, 0.4, 0.6, 0.8, 1, and 3 M). The results
are shown as the meanG SEM of at least three independent experiments (p< 0.0001, folded wt-p53 versus folded M237I-
p53 and wt-p53 G50% versus M237I-p53 G50%).
(G and H) bis-ANS fluorescence spectra of wt- and M237I-p53C proteins under (G) folded and (H) 50% unfolded (at the
G50%) conditions, respectively.
See also Figures S14C and S14D.
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with significantly increased accumulation of the latter proteins. Aggregation of mutant p53 has been shown
to impair the tumor suppressor activities of p53 and contribute to the gain of oncogenic phenotypes
including chemoresistance. In high-grade serous ovarian carcinoma, p53 aggregation is related to plat-
inum resistance (Yang-Hartwich et al., 2015). Our findings link TMZ chemoresistance in glioblastoma to a
mutant-specific p53 aggregation phenotype.
One of initial modifications required for dissociation of the p53 negative regulator MDM2 and activation of
transcriptional activity is p53 phosphorylation at Ser15 (Dumaz and Meek, 1999; Shieh et al., 1997). Further-
more, cellular homeostasis is dictated by protein synthesis, degradation, and repair. When protein folding
efficiency is threatened owing to protein overload within the ER, cells experience ER stress and activate the
UPR (Hetz, 2012; Walter and Ron, 2011). If mutant p53 production exceeds the rates at which ER quality
checks manage recently synthesized proteins, cells face a bottleneck in protein control. The expression
of the two UPR sensors, inositol-requiring protein-1a (IRE-1a) and protein kinase RNA-like ER kinase
(PERK), supports ER stress due to the overload of misfolded mutant p53 species. These two sensors partic-
ipate in prosurvival signaling to eliminate misfolded species, reduce the transcription of mRNAs and in-
crease the concentration of molecular chaperones to process accumulated proteins within the ER (Hetz
et al., 2011).
Hsp90 is an ER-resident molecular chaperone that promotes proper folding and maturation of client pro-
teins (Zhao et al., 2005). However, Hsp90 was previously shown to participate in the adaptive response of
cancer cells by stabilizing and preventing degradation of overexpressed mutant p53 (Finlay et al., 1988;
Whitesell et al., 1997, 1998). We speculate that Hsp90 might fail to chaperone the chemoresistance mutant
p53, but the expression of equally high Hsp90 levels in U87 (wt-p53) and T98G cells indicate that other
escape mechanisms may favor M237I accumulation and aggregation. Unfortunately, we were not able to
rule out other potential escape mechanisms, such as impairment of the p53 degradation system. Hsp90
has been shown to chaperone recombinant wt p53 by positively modulating its DNA-binding ability at
physiological temperatures (Walerych et al., 2004), and the DNA-binding domain of p53 adopts a molten
globule-like state as it transiently binds to Hsp90 (Park et al., 2011). Recently, long-term Hsp90 inhibition
was shown to extend the survival of R248Q p53-and R172H p53-expressing mice but not their correspond-
ing p53(/) littermates (Alexandrova et al., 2015). Hsp90 and other cochaperones can also effectively
distinguish wt p53 and mutant p53 conformations, as Hsp90 selectively binds to wt p53 but not to the hot-
spot mutant R175H p53, and other cochaperones are first required prior to the Hsp90-R175H p53 interac-
tion (King et al., 2001). The effects of p53 mutations on its structure may trigger a divergent chaperone
cellular response impairing proper p53 turnover. In support of this finding, the Hsp90 inhibitor geldanamy-
cin was previously shown to either stimulate cytoplasmic mutant p53 translocation into the nucleus or in-
crease mutant p53 ubiquitination and proteasome-mediated degradation (Whitesell et al., 1997, 1998).
Notably, some destabilized mutant p53 proteins exhibit conformational changes that are sufficient to
threaten chaperone activity and enhance aberrant stability.
The differences in the oligomer composition and localization of the wt and M237I p53 oligomers in living
cells are also intriguing. Notably, the oligomeric species detected by N&B analysis in living cells are not
necessarily the same as those amyloid oligomers revealed by immunofluorescence assays. Amyloid species
detected by the oligomer-sensitive antibody are likely large species owing to their close association with
chaperones or other p53 family members (Xu et al., 2011). Meanwhile, those observed by N&B most likely
represent the initial association steps of p53multimers, such as octamers or limitedmultimers. In support of
this finding, p53 octamers were recently shown to bind p53 response elements (REs) containing long
spacers (Vyas et al., 2017). It is tempting to speculate that destabilized p53 mutations such as M237I would
favor p53 octamers to form rapidly and bind to REs related to gain-of-function phenotypes. However, the
identification of amyloid features of these initial multimers requires further investigation. We present evi-
dence of oligomers consisting of a chemoresistant mutant p53 that are larger than the active p53 tetrameric
WT-p53C M237I-p53C
k1 (min
1) 4.13104G 3.7 3 106 0.481G 0.007
k2 (min
1) 5.93103G2.7 3 104 2.371G 0.097
Table 1. Kinetic Parameters according to First-Order Lag Kinetics
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form inside the nuclei of living cells (Figures 3 and 4). Although a previous report using N&B analysis
showed that the balance among wt p53 monomers, dimers, and tetramers is not determined simply by
p53 concentration (Gaglia et al., 2013), our results indicate that oligomers formed by cancer-associated
mutations are concentration-dependent. In contrast to wt p53, for which we mostly detected monomers
and dimers throughout the cytosol and nucleus, M237I p53 tetramers were abundant in the cytosol, and
M237I p53 oligomers (at least those larger than tetramers) were densely distributed within the nucleus (Fig-
ure 4). As DNAdamage was not chemically induced in our cells, we considered the imaged cells to be under
resting conditions. Consistent with this finding, the distribution of wt p53monomers and dimers conformed
to previous estimations (Gaglia et al., 2013). Surprisingly, M237I p53 tetramers were present in the cytosol.
The tetramerization domain of p53, which contains a nuclear export signal (NES, residues 340–351), has
been shown to be occluded as tetrameric p53 is formed, which forces p53 tetramers to remain in the nu-
cleus (Stommel et al., 1999). According to this model, the monomeric and dimeric forms of p53 would
have an exposed NES motif, allowing them to be shuttled to the cytosol. Based on our observations of
M237I p53 tetramers in the cytosol, we speculated that M237I p53 dimers present in the cytosol adopt a
conformation amenable to the formation of stable tetramers. Given the potential non-transcriptional roles
of p53 (Green and Kroemer, 2009), the presence of functional mutant p53 tetramers in the cytosol of cancer
cells may represent an unsolved conundrum that should be investigated. Furthermore, because the olig-
omerization status of p53 is linked to the cell fate, as p53 dimers show growth arrest but not apoptotic func-
tions like tetramers (Fischer et al., 2016), the presence of p53 tetramers in the cytosol and larger oligomers
in the nuclei of cancer cells may help us to understand the oncogenic activities in cancer. A recent contri-
bution from the Prives group showed that the oligomerization status of p53 substantially impacts p53-
MDM2 regulation and p53 localization, raising questions about how p53 tetramers are degraded (Katz
et al., 2018). The functionality of oligomers larger than tetramers in the nucleus is challenging to address,
but based on previous works from our group (Ano Bom et al., 2012; Bom et al., 2010; Ferraz da Costa et al.,
2018; Ishimaru et al., 2009; Ishimaru et al., 2003a, 2003b; Levy et al., 2011; Pedrote et al., 2018; Rangel et al.,
2019; Silva et al., 2018) and others (Ghosh et al., 2017; Kluth et al., 2014; Lasagna-Reeves et al., 2013; Soragni
et al., 2016; Xu et al., 2011; Yang-Hartwich et al., 2015), we believe these oligomers participate in oncogenic
transformation and cancer gain-of-function phenotypes. The oligomers identified in this work are formed
by a chemoresistant mutant p53 present in glioblastoma tumors. It is tempting to suggest that the cellular
environment limits misfolding and massive aggregation, especially by interacting with chaperones. This
would lead to the formation of small oligomers that might exert gain-of-function effects. Notably, the nu-
cleus is full of nucleic acids and especially RNAs, which were recently shown to limit p53 aggregation but
facilitate small oligomer formation (Kovachev et al., 2017).
The presence of M237I p53 amyloid oligomers in glioblastoma cells (Figure 1) and the nuclear M237I p53
oligomers captured in live cells (Figures 3 and 4) indicate that mutant p53 destabilized conformations are
present in cells and that, by evading the protein control apparatus, these aberrant p53 forms undergo olig-
omerization. Therefore, it is important to explore the mechanisms by which cancer-associated p53 muta-
tions affect its folding. The polypeptide fold is extremely dependent on either its amino acid composition
or the environment surroundings. The hydration of nonpolar amino acids occurs prior to amyloid aggrega-
tion and is often assessed by pressure perturbation experiments (Cordeiro et al., 2004; de Oliveira and
Silva, 2015; Ferra˜o-Gonzales et al., 2003; Silva et al., 2014b; Silva et al., 2010). Pressure increments favor wa-
ter infiltration within the protein nonpolar core, providing an opportunity to assess destabilized hydrated
states (de Oliveira and Silva, 2015). Hydration effects in protein misfolding and amyloid conversion have
been studied over the past 20 years in several macromolecular systems (Pedrote et al., 2018; Silva et al.,
2018; Silva et al., 2010). Here, the ‘‘swollen states’’ captured for M237I-p53 are more hydrated than those
formed by wt-p53, explaining mutant sensitivity to water infiltration and the loss of structural rigidity.
The p53 fold offers an opportunity to track conformational changes by reporting the fluorescence of its Tyr
and single Trp residues. In the native state, the major signal comes from the Tyr residues, whereas the sin-
gle Trp residue is quenched owing to the transfer of energy between Tyr residues within the excited state.
Once p53 starts to unfold, Trp quenching is lost and Trp fluorescence becomes the major contribution to
the signal (Bullock et al., 2000). Furthermore, the Tyr residues within p53C (eight in total) are spread
throughout the entire domain, which offers an additional advantage to map overall hydration in this
case. By reporting the fluorescence of these internal probes, we have shown the origins of the destabiliza-
tion of mutant p53 in solution. Furthermore, these destabilized M237I-p53 states are preamyloidogenic
species in solution, as revealed by the rapid ThT kinetic traces, negative stainingmicroscopy, and increased
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protein hydrophobicity in the solvent. In cell-based approaches, M237I-p53 is strongly expressed in che-
moresistant glioblastoma cells under ER stress and accumulates to the same level as the amyloid species.
AlthoughM237I is not classified as a hotspot mutation, similarities in terms of thermodynamic stability, location,
and ability to disrupt DNA binding between the M237I-p53 mutant and the R175H p53 structural mutant were
previously reported (Bullock et al., 2000). Using molecular dynamic simulations, we observed regions within the
DNA-binding domain of wt-p53 and the hotspot R175H-p53 mutant with an elevated incidence of exposed
backbone hydrogen bonds (BHBs) compared with those of the p53 family members p63 and p73 (Cino et al.,
2016). Protection of BHBs is an important feature of structural stability and the ability to form amyloid assemblies
(Fernandez et al., 2003). Hydrophobic shielding of BHBs may reduce hydration by preventing the interaction of
labile bonds with water molecules. In the case ofM237I-p53, movement of the Ile side chain away from the Zn2+-
binding motif may expose labile BHB sites for hydration. We did not investigate the effects of the M237I-p53
mutation on Zn2+ displacement, but the related R175H hotspotmutation accelerates the rate of Zn2+ loss (Butler
and Loh, 2003). Notably, underprotected BHBs, also called dehydrons, act as sites for water attack, promote am-
yloid formation, and can be used as a strategy to target aggregation (Accordino et al., 2013;Wilcken et al., 2012).
Recently, we have been pursuing different strategies to prevent p53 aggregation (Ferraz da Costa et al., 2018;
Pedrote et al., 2018; Rangel et al., 2019; Silva et al., 2018). More importantly, the M237I mutation is fairly close to
the previously identified underprotected BHB regions, reinforcing the role of hydration in p53 amyloid aggrega-
tion (Cino et al., 2016). We believe that this mutation disturbs the fragile wt-p53C structure by increasing hydra-
tion andprotein hydrophobicity to the solvent. If increasedhydrationproves tobe common toother destabilized
p53mutations, p53 dehydronsmaybe used as an alternative platform to avert the gain-of-function phenotype of
oligomeric p53 compositions.
Limitations of the Study
Caveats of this work include the absence of isogenic cell lines in our experiments and testing the chemo-
resistant p53 mutation in other cancer cells to directly attribute the chemoresistance phenotype to aggre-
gated p53 species. Another drawback is that we are not able to certify whether the oligomeric states
captured by the N&B analysis present the typical features of amyloids.
METHODS
All methods can be found in the accompanying Transparent Methods supplemental file.
SUPPLEMENTAL INFORMATION
Supplemental Information can be found online at https://doi.org/10.1016/j.isci.2020.100820.
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Supplementary Figure 1. Chemoresistant features of glioblastoma derived cells, Related to Figure 1. 
a, Agarose strips of wt p53-expressing (U87) and M237I p53-expressing (T98G) glioblastoma cells 
shows MGMT and PTEN transcript levels; 
b, c, Dot plots showing MGMT and PTEN transcript levels, respectively, in wt p53-expressing (U87) and 
M237I p53-expressing (T98G) glioblastoma cells; 
d, Bright-field images of U87 and T98G glioblastoma cells after 0, 8, and 24 h of scratch experiments; 
e, Dot plot showing the migration rates following scratch experiments with wt p53- and M237I p53-
expressing glioblastoma cells. The results are shown as the mean ± s.e.m. of (n = 4) area measurements 
from two independent scratch experiments (** P = 0.0024, **** P < 0.0001); 
f, Dot plot showing the viability of wt p53- and M237I p53-expressing glioblastoma cells to 
temozolomide (TMZ) treatment. (-) Untreated cells; (v.) Mock condition. The results are shown as the 
mean ± s.e.m. of (n = 3) independent experiments (* P = 0.0199, ** P = 0.0081, **** P < 0.0001, and ns 
not significant); 
g, Agarose strips of p53, MGMT, PTEN, and GAPDH of wt p53- (U87) and M237I p53-expressing 
(T98G) glioblastoma cells after 12, 24, and 48 h of TMZ treatment. (L) ladder; (*) Mock condition; (-) 
Negative controls;  
h, Scatter plots showing the levels of p53, MGMT, and PTEN transcription in wt p53- (U87) and M237I 
p53-expressing (T98G) glioblastoma cells after 12, 24, and 48 h of TMZ treatment.  
Supplementary Figure 2. Representative immunofluorescence assays and quantification, Related to 
Figure 1. 
a-p, Immunofluorescence panels for (a-d) wt p53-expressing (U87), (e-h) wt p53-expressing (GBM11), 
(i-l) R273H p53-expressing (U138), and (m-p) M237I p53-expressing (T98G) glioblastoma cells showing 
p53 colocalization (white arrows) with amyloid oligomers. Scale bars, 20 µm; Insets, 5 µm; 
q-ff, Immunofluorescence panels for (q, r) wt p53-expressing (U87), (s, t) wt p53-expressing (GBM11), 
(w, z) R273H p53-expressing (U138), and (aa, bb) M237I p53-expressing (T98G) glioblastoma cells 
showing merged p53 and amyloid oligomer channels used for pixel-by-pixel quantification. (u-y) and (cc-
ff) show the pixel-by-pixel correlation plots between p53 and oligomer channels. Regions 1, 2, and 3 were 
classified as +/-, -/+, and +/+ (p53/oligomers). Pixel frequency is color-coded. Pixels within the double 
positive region 3 indicate colocalization between p53 and oligomers.        
 Supplementary Figure 3. DNA sequencing alignments of wt p53-expressing (U87 and GBM11) and 
M237I p53-expressing (T98G) glioblastoma cells showing the TP53 gene region encoding the p53 DNA-
binding domain. (*) ATG-to-ATA codon substitution leading to Met-to-Ile at position 237, Related to 
Figure 1.      
     
 Supplementary Figure 4. Immunofluorescence quantification by Pearson’s coefficient,  
Related to Figure 1. 
a-p, Immunofluorescence panels for (a-d) wt p53-expressing (U87), (e-h) wt p53-expressing (GBM11), 
(i-l) R273H p53-expressing (U138), and (m-p) M237I p53-expressing (T98G) glioblastoma cells showing 
p53 (green), amyloid oligomers (red), nuclei (blue), and merged channels (white arrows). Scale bars, 20 
µm;  
q, Dot plot showing Pearson’s coefficient for p53 / oligomer colocalization of (n = 5) immunofluorescent 
images. (*) 0.01 < P < 0.05; (ns) Not significant.   
 Supplementary Figure 5. Oligomeric species in M237I p53-expressing (T98G) glioblastoma cells, 
Related to Figure 1. 
a, Immunoblot (IB) membrane showing fluorescent staining of p53 species after immunoprecipitation 
(IP) of p53 from M237I p53-expressing (T98G) glioblastoma whole cell extracts; 
b, Line plot of the absorbance at 280 nm as a function of the elution volume showing the size exclusion 
pattern of M237I p53-expressing (T98G) glioblastoma and null-p53 H1299 carcinoma whole cell 
extracts. (Vo) Void volume; (k) kiloDaltons; 
c, Dot blots showing p53 fluorescent staining of labeled (A-D) fractions in (b). 
Experiments were performed twice with similar results.          
 Supplementary Figure 6. Full immunoblot membranes showing proteins detected in this work, Related 
to Figure 2.   
 
Supplementary Figure 7. Immunoblots for UPR sensors, Related to Figure 2. 
a, Immunoblot (IB) strips showing the protein levels of inositol-requiring protein-1α (IRE-1α), protein 
kinase RNA-like ER kinase (PERK), and heat shock protein 90 (Hsp90) in glioblastoma and H1299 cells; 
b-d, Dot plots showing densitometry values obtained after normalizing PERK, IRE-1α, and Hsp90 levels 
to those of β-actin, respectively. The results are shown as the mean ± s.e.m. of (n = 3) densitometry 
measurements. Experiments were performed twice with similar results (**** P < 0.0001, ** P = 0.0018, 
and ns not significant). 
Supplementary Figure 8. Confocal images of EGFP-, wt p53-EGFP- and M237I p53-EGFP-transfected 
H1299 cells showing p53 puncta distribution (white arrows) within cytosolic and nucleolar 
compartments, Related to Figure 3. Scale bars, 10 µm; 
  
Supplementary Figure 9. N&B experimental settings, Related to Figure 3. 
a, b, Representative frames for (a) wt p53-EGFP- and (b) M237I p53-EGFP-transfected H1299 imaged 
cell used as input for statistical number and brightness (N&B) analysis; 
c, d, Representative line plots of the fluorescence intensity as a function of frames for (c) wt p53-EGFP- 
and (d) M237I p53-EGFP-transfected H1299 imaged cell showing low photobleaching contribution (less 
than 10%) through acquired frames.    
   
Supplementary Figure 10. EGFP brightness normalization, Related to Figure 3. 
a, Representative brightness plots of (n = 7) EGFP-transfected cells used to normalize brightness levels of 
monomeric EGFP; 
b, Pixels corresponding to the immobile fraction i.e., background (red) and those from the EGFP protein 
(green) were selected from Gaussians of brightness distributions; 
c, Brightness distributions of studied cells. Fitted gaussians (red and green) were used to depict pixel 
distributions in imaged cells (b).       
Supplementary Figure 11. Intensity, brightness, and number of molecule maps, Related to Figure 3. 
a-c, Intensity, brightness, and number of molecule maps of (a) EGFP-, (b) wt p53-EGFP-, and (c) M237I 
p53-EGFP-transfected H1299 cells. One imaged wt p53-transfected cell exhibited equally brighter pixels 
within the nuclear region when compared to M237I p53-transfected cells (red asterisk). Red arrows show 
increased number of wt p53 molecules not predominantly overlapping with bright pixel regions; Green 
and white arrows show wt- and M237I-p53 containing increased number of molecules overlapping with 
brighter pixels, respectively.        
  
Supplementary Figure 12. WT- and M237I p53-EGFP brightness distributions, Related to Figure 4. 
a, b, Representative cells showing (a) M237I p53-EGFP and (b) wt p53-EGFP brightness plots, intensity, 
B, and N maps. Arrows colored white and red show the same as in Supplementary Figure 11.   
 
Supplementary Figure 13. Higher-order oligomeric states captured by N&B analysis,  
Related to Figure 4. Representative brightness plots of wt p53-EGFP-transfected H1299 cells showing 
pixels with higher B values (red rectangles) and their distribution within the cells (green arrows). 
      
Supplementary Figure 14. Wt- and M237I p53 DNA-binding domain (p53C) behavior in solution, 
Related to Figures 5 and 6. 
a, Ribbon representation of the p53C structure (PDB 2FEJ). L1-L3 stands for loop regions. Zoomed-in 
image shows the Zn2+-binding site. Residues coordinating the Zn2+ ion are highlighted as sticks. Met-to-
Ile substitution at position 237 is shown as spheres to emphasize side chain dislocation; 
b, Line graph showing first derivative of the chemical-induced wt- and M237I p53C unfolding; 
c, d, Kinetic traces showing (c) light scattering and (d) thioflavin T binding to wt- and M237I p53C.          
Transparent Methods 
Cell culture. The human glioblastoma cell lines used in this study comprised U87 (carrying wt-
p53), T98G (carrying M237I-p53), U138 (carrying R273H-p53) (Cell lines were obtained from 
The Rio de Janeiro Cell Bank (BCRJ) and GBM11 (carrying wt-p53). The human H1299 non-
small-cell lung carcinoma cell line was used as a model for null p53 (BCRJ). GBM11 cells were 
obtained by surgical biopsy from a 57-year-old male patient bearing a recurrent glioblastoma 
previously treated with TMZ concomitantly with radiotherapy, who had given written consent to 
the study. All procedures were in agreement with the Brazilian Ministry of Health Ethics 
Committee (CONEP no. 2340). GBM11, T98G, and U87 cells were cultured in DMEM/F12; 
U138 cells were cultured in DMEM, and H1299 cells were cultured in RPMI-1640 medium. All 
cells were supplemented with 10% fetal bovine serum and maintained at 37°C in a humidified 
atmosphere containing 5% CO2. Cell lines were certified by STR genotype with their identity 
checked against the American Type Culture Collection (ATCC) STR profile. 
DNA sequencing. Exons 5 to 8 of the TP53 gene corresponding to the p53 DNA-binding domain 
from U87, T98G, and GBM11 cells were amplified with the p53 primers described in 
Supplementary Table 1 and purified using 1 unit (U) of FastAP thermosensitive alkaline 
phosphatase and 5 U of exonuclease I as follows: 37°C for 30 min and 85°C for 15 min. Purified 
products were directly submitted to DNA sequencing using an Applied Biosystems (ABI 3130) 
instrument. Sequence analysis of wt-TP53 and TP53 with a codon substitution to generate a Met-
to-Ile mutation at position 237 in T98G cells (Supplementary Fig. 3) was performed using 
AlignX Invitrogen Corporation and Chromas Lite 2.1 software. 
Wound-healing assay. Based upon the migration capacity of cells, we tested the motility of wt- 
and M237I-p53-expressing cells by a wound-healing assay (Liang et al., 2007). We cultured U87 
and T98G cells on 12-well plates as described above. After washing the cells with phosphate-
buffered saline (PBS, 140 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4), we 
scratched the monolayer with a 10 µL sterile plastic tip, and fresh media was added. We followed 
wound coverage at 0, 8, and 24 h after scratch by bright-field imaging. Quantification of cell 
recovery was determined using the following formula: wound area / total area × 100. 
Experiments were performed in duplicate.      
       
Chemosensitivity assays. We cultured U87 and T98G cells in 24-well plates as described above. 
A TMZ stock (25 mM) was prepared in DMSO and stored at -80°C. TMZ solutions were directly 
diluted in fresh media to final concentrations of 100 and 200 µM (the final DMSO concentration 
was 0.008%). Cells were washed every day, and a new bolus of TMZ was added. Untreated cells 
were used as a control. We quantified cell viability by counting cells that excluded Tripan blue 
staining after 72, 96, and 144 h. Data are shown as the mean ± s.e.m. of several replicates. 
Immunofluorescence. GBM cell lines (U87, T98G, U138 and GBM11) were grown on cover 
slips, washed twice with PBS, fixed in a formaldehyde solution (3.7%) and permeabilized with 
Triton X-100 (0.25%). Cells were then incubated with 5 mM ammonium chloride for 30 min and 
blocked for nonspecific antigenic sites for 1 h in 3% bovine serum albumin (BSA) (Sigma, 
#a7030) prepared in PBS. Next, cells were simultaneously labeled with a 1:200 dilution of 
mouse DO-1 monoclonal anti-p53 antibody (Santa Cruz, Inc. #sc-126) and a 1:1,000 dilution of 
A-11 anti-oligomer antibody (Millipore, #AB9234) overnight at 4°C in a humidified chamber. 
Cells were extensively washed with PBS and incubated with anti-mouse fluorescein 
isothiocyanate (FITC) 488 (Sigma, #F0257) and anti-rabbit IRDye® 680LT-conjugated (Li-Cor, 
#925-68023) secondary antibodies for 1 h at room temperature in a dark chamber. Finally, cells 
were washed with 3% BSA prepared in PBS, followed by extensive washes with PBS and fixed 
with Prolong® Gold Antifade Reagent with DAPI (Molecular Probes, #8961). 
Confocal imaging. Immunofluorescence images were acquired with the LSM 510 Meta confocal 
laser scanning microscope (Carl Zeiss, Inc.) using excitation wavelengths of 488, 561 and 350 
nm. For quantification analysis, ImageJ plugin JACoP (Just Another Colocalization Plugin) was 
used to analyze all immunofluorescence glioblastoma cell images, and Pearson coefficients were 
used to measure colocalization between p53 and oligomers. Five different images were used to 
calculate Pearson coefficients, which were plotted using GraphPad Prism 7. For fluorescence 
fluctuation spectroscopy, images were acquired with an ELYRA LSM 710 confocal laser 
scanning microscope (Carl Zeiss, Inc.) using an excitation wavelength of 488 nm and an EC 
Plan-Apochromat 63×/1.4 oil objective. During imaging, laser power was reduced to 0.2% to 
avoid fluorophore bleaching (Supplementary Fig. 9). For N&B statistical analysis, we imaged a 
stack of 100 frames within an interval of approximately 2 min. Image sizes were 256 by 256 
pixels, and the acquisition time was 12.61 µs/pixel. Cells from different preparations (n=10 cells 
for each studied condition) were imaged. 
  
RT-PCR. A total of 7×106 cells were washed with PBS, and RNA extraction was performed 
using the standard TRIzol protocol (Invitrogen, #15596026). After measuring the RNA 
concentration, 2 µg of total RNA was used for reverse transcription. The complementary DNA 
(cDNA) reaction mixture was composed of 0.8 µL 25 mM deoxynucleotide triphosphates 
(dNTPs) (Promega, #U1201), 2 µL 0.1 M dithiothreitol (DTT), 1 µL 100 pM random primer 
solution (Invitrogen, # 48190-011), 4 µL 5× buffer solution (Invitrogen), 1 µL 200 µg/µL 
Moloney murine leukemia virus reverse transcriptase (Promega, #M1701) and 1 µL 20U/µL 
RNAse inhibitor (Invitrogen, #AM2694). RNA solutions were heated at 65°C and placed on ice 
for 10 min, followed by incubation with the cDNA reaction mixture at 42°C for 40 min. 
Enzymes were inactivated at 65°C for 5 min, and cDNAs were stored at -20°C. Target primers 
are listed in Supplementary Table 1. PCR was carried out with 0.3 µL 5 U/µL Taq DNA 
polymerase (Phoneutria, #TAQPHT), 10× Buffer (Phoneutria, #TAQPHT), 1.5 mM MgCl2, 0.15 
mM dNTPs and 100 pM of each primer. Cycling conditions involved an initial denaturation step 
at 94°C for 5 min, followed by 30 cycles of 94°C for 30 sec + 57.5°C (for p53 and GAPDH), 
55°C (for MGMT) or 58°C (for PTEN) for 1 min and 72°C for 1 min, with a final extension step 
at 72°C for 10 min. We visualized amplified products in 1% agarose gels stained with Gel Red 
(Biotium, #41003), and densitometric analysis was performed with ImageJ software, v. 1.43r 
(National Institutes of Health, USA). 
Immunoblots. To prepare protein extracts, cells were washed with PBS and lysed with RIPA 
buffer containing 150 mM sodium chloride, 1% NP-40, 0.5% deoxycholate, 0.1% sodium 
dodecyl sulfate, 50 mM Tris-Cl (pH 8.0) and 1× protease inhibitor cocktail (Sigma, #P8340). The 
protein concentration was determined as described by Lowry et al. (1951) using BSA (Sigma, 
#a7030) as a protein standard. One hundred micrograms of protein extracts were loaded onto 
SDS-PAGE gels (15%), transferred to polyvinylidene difluoride (PVDF) membranes 
(Uniscience, #926-31098) using the Semidry system (Bio-Rad, #170-3940), blocked for 1 h at 
4°C in Odyssey® Blocking Buffer (Uniscience, #927-50000) and incubated overnight at 4°C 
with specific primary antibodies. The following antibodies and dilutions were used: anti-p53 
(DO-1, Santa Cruz Biotechnology, Inc., sc-126), 1:200; anti-oligomer (A11, Millipore, 
#AB9234), 1:1,000; anti-GAPDH (Santa Cruz Biotechnology, Inc., #0411), 1:1,000; and anti-β-
actin (Sigma, #A1978), 1:8,000. The membranes were washed 4 times with Tris-buffered saline, 
TBS (50 mM Tris-Cl, 150 mM NaCl, pH 7.5) and incubated for 1 h with IRDye® 800CW-
labeled mouse (Uniscience, #926-32210) and rabbit (Uniscience, #926-32211) secondary 
antibodies diluted at 1:10,000. After 4 additional washes with TBS, visualization was carried out 
using the LI-COR Odyssey® scanner and software (LI-COR Biosciences). Densitometric 
quantification of bands was performed using ImageJ software, v. 1.43r (NIH, USA). For 
immunoprecipitation (IP) assays, we used Protein A/G Plus-agarose beads (Santa Cruz 
Biotechnology Inc., #sc-2003) following manufacture instructions and 500 µg of whole U87 and 
T98G cell extracts.         
        
Analytical size exclusion chromatography. Whole T98G and H1299 cell extracts were directly 
injected into a Superdex 200 10/300 GL (GE Lifesciences, #29-0915-96). All runs were 
performed in PBS (140 mM NaCl, 2.8 mM KCl, 10 mM Na2HPO4, and 1.8 mM KH2PO4, pH 
7.4) at a flow rate of 0.7 mL min−1, and the absorbance was monitored at 280 nm using a high 
performance liquid chromatograph system (Shimadzu). The column was previously calibrated 
using thyroglobulin, 670 kD; γglobulin, 158 kD; ovalbumin, 44 kD; myoglobin, 17 kD; and 
vitamin B12, 1.35 kD (Bio-Rad, #151-1901). 
p53 protein preparations. To recombinantly express p53C constructs, the pET15b vector 
containing the core domain of wt- (Addgene, #24866) and M237I-p53 (introduced by site-
directed mutagenesis) was transformed by heat shock into the BL21(DE3) E. coli strain, which 
was grown overnight at 37°C on LB agar with 100 µg/mL ampicillin. Cells were then grown 
with shaking at 180 rpm in LB to an A600 nm of approximately 0.8 at 37°C, which was followed 
by T7 promoter induction with 1 mM isopropyl β-D-thiogalactoside; cells were then maintained 
at 25°C with shaking at 180 rpm for 2 h prior to a temperature decrease to 15°C overnight. Cells 
were harvested by centrifugation for 15 min at 10,000 × g and 4°C and stored at -20°C or 
resuspended in buffer A (50 mM Tris-Cl (pH 7.4) containing 150 mM NaCl, 5 mM DTT and one 
tablet of EDTA-free protease inhibitor cocktail (Sigma-Aldrich, 16424900)). Cells were 
sonicated, and soluble proteins were harvested through centrifugation at 18,000 × g for 15 min at 
4°C. The supernatant was loaded onto Ni-NTA Superflow resin (Qiagen, #30450) previously 
equilibrated in buffer A using an Äkta Prime system at a flow rate of approximately 0.8-1 mL/
min. The column was then washed with buffer A until A280 nm baseline stabilization, and weakly 
bound proteins were eluted with 5 column volumes of 5% buffer B (buffer A plus 0.5 M 
imidazole). p53 was eluted using a linear gradient of 5–100% buffer B. His-tag cleavage was 
performed using thrombin at a thrombin/protein ratio of 1:3,000 (w/w) for 2 h. Cleaved proteins 
were then loaded onto a Sephacryl 16/60 S-100 preparative column (GE Healthcare) equilibrated 
with buffer A as a final step to achieve high-purity p53C. The protein concentration was 
determined by A280 nm using an extinction coefficient of 17,420 M-1.cm-1. Glycerol (5%) was 
added to p53 constructs before storage in liquid nitrogen. 
LS measurements. LS was used to follow protein aggregation in pressure-induced 
measurements and kinetic experiments at physiological temperature. Samples were excited at 
320 nm, the emission from 300 to 400 nm was recorded, and data were expressed as the area 
under the LS curve using an ISSK2 spectrofluorometer (ISS, Inc.). The sample concentration 
was 5 µM in 50 mM Tris-Cl (pH 7.4) containing 150 mM NaCl and 5 mM DTT. p53 samples 
were routinely centrifuged at 8,000 rpm 10 min prior to the experiments to eliminate any residual 
traces of aggregation. 
ThT kinetics. ThT (25 µM) kinetics were recorded using 5 µM wt- or M237I-p53C in an ISSK2 
spectrofluorometer (ISS, Inc.) upon excitation at 450 nm and emission at 471 nm under mild 
agitation. Reactions (total volume, 1 mL) were placed in a square cell with magnetic stirrers 
(Hellma, #109004F-10-40) and temperature control (Quantum Northwest, #TC125) at 37°C 
throughout the assay. Experiments were performed three times with different protein 
preparations, and the results are expressed as the mean ± s.e.m. Mathematica (Wolfram) was 
used to calculate k1 and k2 rate constants according to the first-order equation below. Fitting of 
the data to the model can be obtained in the previously reported study (Pedrote et al., 2018). 
 , 
where F is the intensity of ThT fluorescence as a function of time, t, and amplitude, m, is defined 
as the concentration of the monomeric protein multiplied by the raw fluorescence signal of ThT 
bound to the aggregate at the end of the kinetic experiment. The term k3t is a small linear term 
related mainly to machine drift, and the parameter a is included to allow for a nonzero intercept 
at t = 0. 
Transmission electron microscopy. Images of wt- and M237I-p53 were obtained after a 2 h 
incubation at 37°C or 2.68 kbar at 25°C. Samples 4 µL in volume were applied for 1 min to 
previously discharged carbon film on 200 mesh copper grids (EMS, #CF200-cu), gently dried 
with filter paper and stained for 5 sec with 2% uranyl acetate. Negatively stained images were 
acquired on a Philips Tecnai microscope operated at 80 kV at 21,000× and 46,000×. 
Transfection.. Cells were plated on 35-mm dishes containing 14 mm glass coverslips (MatTek, 
#P35G-1.5-14-C), and transfection was performed using Lipofectamine 2000 reagent 
(Invitrogen) according to the protocol provided by the manufacturer. Cells transfected with 5 or 
10 µg pEGFP-N1 vectors (Clontech) bearing the EGFP-tagged sequence at the C-terminus of the 
full-length wt-p53 sequence (Addgene, #11770) were imaged after 24, 48, and 72 h. For N&B 
experiments, cells were imaged after 24 h of transfection. The M237I-p53 mutation was 
introduced by site-directed mutagenesis using GenScript services and confirmed by DNA 
sequencing. The pEGFP-N1 null vector was used to express monomeric EGFP to standardize the 
brightness scale. 
N&B statistical analysis. N&B applies pixel-by-pixel statistical analysis of the fluorescent 
intensity distribution within a stack of images. The average intensity (<K>) can be obtained by 
measuring the fluorescent signal of each corresponding pixel in the stack, and according to the 
intensity fluctuations at each of these pixels, we know how broad the distribution, meaning the 
variance (σ2), is. The larger the variance is, the fewer molecules there are that contribute to the 
average, while the brighter the molecule is. The apparent brightness (B) is then defined by the 
ratio of the variance over the average intensity (σ2/<K>); meanwhile, the apparent number of 
molecules (η) is related to the average intensity over the variance (<K>2/σ2). The evaluation of 
image brightness maps (Bmaps) allows the localization and quantification of oligomeric species in 
living cells. As σ2 arises from contributions from (i) the molecular brightness (ε) of the number 
of molecules (η) fluctuating in and out of the excitation volume and (ii) the detector shot noise, B 
can be rewritten as B = εη + 1. Because the immobile fraction (i.e., the background) has no 
particle fluctuation and no σ2 other than the shot noise, we attribute a value of 1 to the immobile 
contribution to B. After standardizing the B value of monomeric EGFP fluorophore 
(Supplementary Fig. 10) and assuming no changes in the quantum yield of EGFP upon 
oligomerization, we can determine the oligomerization status of EGFP-tagged proteins according 
to the number of fluorescent molecules within these aggregates from B = εη + 1. We measured a 
B value of 1.2 for monomeric (η=1) EGFP. We calculated a B value of 1.4 for η=2 (dimers) and 
1.8 for η=4 (tetramers); we can attribute any B values > 2 to η>4 (oligomers larger than 
tetramers). Few pixels with B values higher than 3 and lower than 4 were localized within puncta 
of wt-p53-transfected cells. We can attribute B values within this range to oligomeric states on 
the order of decamers (η=10) and 15-mer species. N&B analysis was performed using the 
SimFCS suite (www.lfd.uci.edu). 
Pressure-induced spectroscopy. Experiments were performed using 5 µM wt- and M237I-p53C 
in 50 mM Tris-Cl (pH 7.4) containing 150 mM NaCl and 5 mM DTT. Fluorescence emission 
was acquired using an ISSK2 spectrofluorometer (ISS Inc.) equipped with a high-pressure 
optical cell (ISS Inc.). The cell contained three 10 mm-diameter sapphire windows placed at 90 
degrees, allowing L-format acquisition of fluorescence measurements. Samples were excited at 
280 nm to measure tyrosine and tryptophan probes, and emission was recorded from 290-400 nm 
at 2 nm increments. Ethanol was used as the hydrostatic liquid, and polypropylene tubing was 
used to seal pressure cuvettes, allowing efficient pressure transfer to the sample. Pressure cycles 
were carried out with increments of approximately 300-500 bars, followed by 5-10 min for 
system acclimation before emission spectra acquisition. The center of spectral mass (v) was used 
according to the equation below to quantify changes in the fluorescence spectra at each pressure 
point. Fi stands for the emitted fluorescence at wavenumber λ. 
+  
Structural analysis. In silico site-directed mutagenesis analysis and structural evaluations were 
carried out in the UCSF Chimera suite (Pettersen et al., 2004). The Met-to-Ile substitution at 
position 237 of the p53 core domain was introduced into the NMR structure of the p53 core 
domain (PDB code 2FEJ) with the Dunbrack backbone-dependent rotamer library (Dunbrack, 
2002). Clashes within 5 Å were minimized by the structure minimization tool implemented in 
Chimera. The structure was rendered by the Kyte-Doolittle hydrophobicity algorithm (Kyte and 
Doolittle, 1982), and maps were displayed as color-coded worms. 
Statistical analysis and reproducibility. We used GraphPad Prism v.6 to perform all statistical 
tests. Based on experimental assays, we assumed normality and equal variances. We performed 
ordinary one-way ANOVA and Sidak’s multiple comparisons tests assuming a single pooled 
variance. Correction of multiple comparisons were based on 95% CI. Values are expressed as the 
mean ± s.e.m. The results of statistical tests are indicated in each figure as * 0.01 < P < 0.05; ** 
0.001 < P < 0.01; *** 0.0001 < P < 0.001; and **** P < 0.0001. 
 All experiments were tested for reproducibility at least twice. Sample groups for each 
experiment were defined as follows: for immunofluorescence assays we used two wt-p53 (U87 
and GBM11) and two mutant p53-expressing (U138 and T98G) cell lines to compare their p53 
aggregation status; to show the chemoresistance phenotype of T98G cells, we used U87 cells for 
comparison as this cell line is a well-known glioblastoma standard, is easy to use, and expresses 
wt-p53. For size exclusion chromatography experiments, we used H1299 cells instead of U87 
cells because the null p53 H1299 cell line is an ideal negative control of p53 species eluted 
within the void fraction. All previous glioblastoma cell lines were used for immunoblot 
experiments to assess the p53 expression levels. For N&B experiments we used H1299 cells for 
transfection as this cell line does not express endogenous p53, is easy to transfect, and can be 
easily examined by microscopy. Endogenous p53 contributes to the oligomerization status of 
transfected wt-p53 and M237I-p53.         
Supplementary Table 1. Primers used for targets: p53, GAPDH, MGMT, and PTEN, Related to Figure 2 
p53
Primer Sequence Product (pb)
Forward 5’ GCT TCT TGC ATT CTG GGA CAG 3’
626
Reverse 5’ CTT CTT TGG CTG GGG AGA GG 3’
GAPDH
Primer Sequence Product (pb)
Forward 5’ ATC ACC ATC TTC CAG GAG GCG 3’
574
Reverse 5’ CCT GCT TCA CCA CCT TCT TG 3’
MGMT
Primer Sequence Product (pb)
Forward 5’ GCA GTA GGA TGG ATG TTT GA 3’
431
Reverse 5’ TAG GAA CTG CTG AGT GGA GA 3’
PTEN
Primer Sequence Product (pb)
Forward 5’ CAG AGA CAA AAA GGG AGT AAC TA 3’
519
Reverse 5’ GCT TTG TCT TTA TTT GCT TTG TC 3’
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